Oncolytic Viruses: A New Frontier in Cancer Therapy

Maged Naser, Mohamed M. Nasr, Lamia H. Shehata

Abstract


Oncolytic viruses (OVs) have surfaced as a promising approach for combating tumors owing to their ability to selectively proliferate within cancer cells, trigger apoptosis, and activate immune responses. Nevertheless, the therapeutic potency of individual OVs is hindered by the intricate and immunosuppressive characteristics of the tumor microenvironment (TME). To tackle these obstacles, the engineering of OVs has become a pivotal area of research. This review spotlights engineering techniques and multimodal combination therapies for OVs aimed at overcoming delivery challenges, viral engulfment, and antiviral immune responses in cancer treatment. The engineering strategies examined involve amplifying in vivo immune responses, enhancing replication efficacy within tumor cells, boosting safety profiles, and refining targeting capabilities , while summarizing ongoing clinical trial data. By persistently refining engineering techniques , we can realize enhanced treatment outcomes and improved quality of life for cancer patients.

Keywords


Oncolytic Viruses, Cancer Treatment, Genetic Engineering, Clinical Trials .

Full Text:

PDF

References


-Russell, Stephen J., Kah-Whye Peng, and John C. Bell. "Oncolytic virotherapy." Nature biotechnology 30.7 (2012): 658-670.

-Bell, John, and Grant McFadden. "Viruses for tumor therapy." Cell host & microbe 15.3 (2014): 260-265.

-Liu, Ta-Chiang, Evanthia Galanis, and David Kirn. "Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress." Nature clinical practice Oncology 4.2 (2007): 101-117.

-Bai, Yang, et al. "Updates to the antitumor mechanism of oncolytic virus." Thoracic cancer 10.5 (2019): 1031-1035.

-Bai, Yang, et al. "Updates to the antitumor mechanism of oncolytic virus." Thoracic cancer 10.5 (2019): 1031-1035.

-Kaufman, Howard L., Frederick J. Kohlhapp, and Andrew Zloza. "Oncolytic viruses: a new class of immunotherapy drugs." Nature reviews Drug discovery 14.9 (2015): 642-662.

-Elhanani, Ofer, Raz Ben-Uri, and Leeat Keren. "Spatial profiling technologies illuminate the tumor microenvironment." Cancer cell 41.3 (2023): 404-420.

-Qian, Junbin, et al. "A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling." Cell research 30.9 (2020): 745-762.

-Qin, Yan, et al. "Cuproptosis correlates with immunosuppressive tumor microenvironment based on pan-cancer multiomics and single-cell sequencing analysis." Molecular cancer 22.1 (2023): 59.

-Bridges, Kate, and Kathryn Miller-Jensen. "Mapping and validation of scRNA-seq-derived cell-cell communication networks in the tumor microenvironment." Frontiers in immunology 13 (2022): 885267.

-Merlo, Lauren MF, et al. "Cancer as an evolutionary and ecological process." Nature reviews cancer 6.12 (2006): 924-935.

-Xiao, Yi, and Dihua Yu. "Tumor microenvironment as a therapeutic target in cancer." Pharmacology & therapeutics 221 (2021): 107753.

-Badrinath, Narayanasamy, Jeong Heo, and So Young Yoo. "Viruses as nanomedicine for cancer." International Journal of Nanomedicine (2016): 4835-4847.

-De Matos, Ana Lemos, Lina S. Franco, and Grant McFadden. "Oncolytic viruses and the immune system: the dynamic duo." Molecular Therapy-Methods & Clinical Development 17 (2020): 349-358.

-Hagedorn, Claudia, and Florian Kreppel. "Capsid engineering of adenovirus vectors: overcoming early vector–host interactions for therapy." Human Gene Therapy 28.10 (2017): 820-832.

-Martinez-Quintanilla, Jordi, et al. "Oncolytic viruses: overcoming translational challenges." The Journal of Clinical Investigation 129.4 (2019): 1407-1418.

-Lu, Shao-Chia, and Michael A. Barry. "Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses." Expert Opinion on Biological Therapy 22.11 (2022): 1359-1378.

-Meggyes, Matyas, et al. "The possible role of CD 8+/Vα7. 2+/CD 161++ T (MAIT) and CD 8+/Vα7. 2+/CD 161lo T (MAIT‐like) cells in the pathogenesis of early‐onset pre‐eclampsia." American Journal of Reproductive Immunology 79.2 (2018): e12805.

-Miko, Eva, et al. "Immune checkpoint molecules in reproductive immunology." Frontiers in immunology 10 (2019): 846.

-Ju, Fei, et al. "Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade." Journal for immunotherapy of cancer 10.6 (2022).

-Pearl, Taylor M., et al. "Oncolytic virus-based cytokine expression to improve immune activity in brain and solid tumors." Molecular Therapy-Oncolytics 13 (2019): 14-21.

-Li, Qingbo, et al. "The gamble between oncolytic virus therapy and IFN." Frontiers in Immunology 13 (2022): 971674.

-Shinoda, Shuhei, et al. "Interferon‐expressing oncolytic adenovirus+ chemoradiation inhibited pancreatic cancer growth in a hamster model." Cancer Science 114.9 (2023): 3759-3769.

-Woo, Jong Kyu, et al. "Dual-Armed Oncolytic Myxoma Virus Encoding IFN-γ and CD47 Promotes Lymphocyte Infiltration and Tumor Suppression of Syngeneic Murine Melanoma." Cancers 15.19 (2023): 4703.

-Briukhovetska, Daria, et al. "Interleukins in cancer: from biology to therapy." Nature Reviews Cancer 21.8 (2021): 481-499.

-Wang, Hongbin, et al. "Viral vectors expressing interleukin 2 for cancer immunotherapy." Human Gene Therapy 34.17-18 (2023): 878-895.

-Heiniö, Camilla, et al. "TNFa and IL2 encoding oncolytic adenovirus activates pathogen and danger-associated immunological signaling." Cells 9.4 (2020): 798.

-Fang, Lin, et al. "Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma." Pharmacological Research 189 (2023): 106701.

-Zhang, Nianchao, et al. "Construction of an IL12 and CXCL11 armed oncolytic herpes simplex virus using the CRISPR/Cas9 system for colon cancer treatment." Virus Research 323 (2023): 198979.

-Kurz, Emma, et al. "Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer." Cancer Cell 40.7 (2022): 720-737.

-Ma, Rui, et al. "An oncolytic virus expressing IL15/IL15Rα combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma." Cancer research 81.13 (2021): 3635-3648.

-Kowalsky, Stacy J., et al. "Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade." Molecular Therapy 26.10 (2018): 2476-2486.

-Yan, Yang, et al. "Inhibition of breast cancer cells by targeting E2F-1 gene and expressing IL15 oncolytic adenovirus." Bioscience Reports 39.7 (2019): BSR20190384.

-Tse, Brian Wan-Chi, et al. "IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms." PLoS One 6.9 (2011): e24241.

-山西恭輔. "Molecular Mechanisms of IL18 in Disease." International Journal of Molecular Sciences 24 (2023): 17170-17170.

-Takacs, Gregory P., Joseph A. Flores-Toro, and Jeffrey K. Harrison. "Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy." Pharmacology & therapeutics 222 (2021): 107790.

-Tian, Lei, et al. "Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity." Nature cancer 3.11 (2022): 1318-1335.

-Wang, Guoqing, et al. "CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma." Molecular Therapy 31.1 (2023): 134-153.

-O’Bryan, Samia M., and J. Michael Mathis. "CXCL12 Retargeting of an Oncolytic Adenovirus Vector to the Chemokine CXCR4 and CXCR7 Receptors in Breast Cancer." Journal of cancer therapy 12.6 (2021): 311.

-Li, Xiaofei, et al. "CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy." Oncoimmunology 11.1 (2022): 2118210.

-Rangsitratkul, Coby, et al. "Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer." Molecular Therapy-Oncolytics 24 (2022): 507-521.

-Oh, Keunhee. "Namhee Lee, Yun-Hui Jeon, 2, 3 Jiyoon Yoo, 2, 3 Suk-kyung Shin, 2, 3 Songyi Lee, Mi-Ju Park, Byung-Jin Jung, Yun-Kyoung Hong, Dong-Sup Lee, 2, 3."

-Liu, Sisi, et al. "Antitumor efficacy of oncolytic herpes virus type 1 armed with GM-CSF in murine uveal melanoma xenografts." Cancer Management and Research (2020): 11803-11812.

-Saffarzadeh, Neshat, et al. "Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy." Journal of Translational Medicine 22.1 (2024): 250.

-Ferrucci, Pier Francesco, et al. "Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma." Cancers 13.6 (2021): 1383.

-Kemp, Vera, et al. "Arming oncolytic reovirus with GM-CSF gene to enhance immunity." Cancer gene therapy 26.9 (2019): 268-281.

-Lee, Jihyun, et al. "Enhanced oncolytic adenoviral production by downregulation of death-domain associated protein and overexpression of precursor terminal protein." Scientific Reports 11.1 (2021): 856.

-Dryja, Parker, et al. "Defects in intratumoral arginine metabolism attenuate the replication and therapeutic efficacy of oncolytic myxoma virus." Journal for Immunotherapy of Cancer 11.6 (2023).

-Costa-Garcia, Marcel, et al. "Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors." Cancer Immunology, Immunotherapy 73.1 (2024): 5.

-50. Mohamed A, Smiley JR, Shmulevitz M. Polymorphisms in the most oncolytic reovirus strain confer enhanced cell attachment, transcription, and single-step replication kinetics. J virology. (2020) 94(4):e01937-19. doi: 10.1128/JVI.01937-19 [DOI] [PMC free article] [PubMed] [Google Scholar]

-Ricordel, Marine, et al. "Vaccinia virus shuffling: deVV5, a novel chimeric poxvirus with improved oncolytic potency." Cancers 10.7 (2018): 231.

-Koodie, Lisa, et al. "Rodents versus pig model for assessing the performance of serotype chimeric Ad5/3 oncolytic adenoviruses." Cancers 11.2 (2019): 198.

-Wang, Jialin, et al. "TS‐2021, a third‐generation oncolytic adenovirus that carried Ki67 promoter, TGF‐β2 5′ UTR, and IL− 15 against experimental glioblastoma." Journal of Medical Virology 96.1 (2024): e29335.

-Lin, Danni, Yinan Shen, and Tingbo Liang. "Oncolytic virotherapy: basic principles, recent advances and future directions." Signal transduction and targeted therapy 8.1 (2023): 156.

-Poppers, Jeremy, et al. "Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein." Journal of virology 74.23 (2000): 11215-11221.

-Chou, Joany, and Bernard Roizman. "The gamma 1 (34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells." Proceedings of the National Academy of Sciences 89.8 (1992): 3266-3270.

-Liu, B. L., et al. "ICP34. 5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties." Gene therapy 10.4 (2003): 292-303.

-Lawler, Sean E., et al. "Oncolytic viruses in cancer treatment: a review." JAMA oncology 3.6 (2017): 841-849.

-59. Chouljenko DV, Ding J, Lee IF, Murad YM, Bu X, Liu G, et al. Induction of durable antitumor response by a novel oncolytic herpesvirus expressing multiple immunomodulatory transgenes. Biomedicines. (2020) 8(11):484. doi: 10.3390/biomedicines8110484 [DOI] [PMC free article] [PubMed] [Google Scholar]

-Mondal, Moumita, et al. "Recent advances of oncolytic virus in cancer therapy." Human vaccines & immunotherapeutics 16.10 (2020): 2389-2402.

-Zhong, Yiye, et al. "Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening." Journal of Hematology & Oncology 17.1 (2024): 36.

-Smith, Theodore, et al. "In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus–adenovirus receptor." Molecular Therapy 5.6 (2002): 770-779.

-Alba, Raul, et al. "Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors." Blood, The Journal of the American Society of Hematology 116.15 (2010): 2656-2664.

-Huang, Zhijian, et al. "Application of oncolytic virus in tumor therapy." Journal of Medical Virology 95.4 (2023): e28729.

-Yang, Ming, et al. "A novel fiber chimeric conditionally replicative adenovirus-Ad5/F35 for tumor therapy." Cancer Biology & Therapy 18.11 (2017): 833-840.

-Menotti, Laura, et al. "HSV as a platform for the generation of retargeted, armed, and reporter-expressing oncolytic viruses." Viruses 10.7 (2018): 352.

-Froechlich, Guendalina, et al. "Generation of a novel mesothelin-targeted oncolytic herpes virus and implemented strategies for manufacturing." International Journal of Molecular Sciences 22.2 (2021): 477.

-Granot, Tomer, Yoshihide Yamanashi, and Daniel Meruelo. "Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity." Molecular Therapy 22.1 (2014): 112-122.

-Yaiw, K. C., et al. "CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy." Gene therapy 18.3 (2011): 313-317.

-Chen, Jieliang, et al. "Functional comparison of interferon‐α subtypes reveals potent hepatitis B virus suppression by a concerted action of interferon‐α and interferon‐γ signaling." Hepatology 73.2 (2021): 486-502.

-Ying, Chang, et al. "GOLPH2-regulated oncolytic adenovirus, GD55, exerts strong killing effect on human prostate cancer stem-like cells in vitro and in vivo." Acta Pharmacologica Sinica 39.3 (2018): 405-414.

-Tian, Lei, et al. "Targeting Fc receptor-mediated effects and the “Don't Eat Me” signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer." Clinical Cancer Research 28.1 (2022): 201-214.

-Xu, Bo, et al. "An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma." Nature communications 12.1 (2021): 5908.

-Hellums, Elizabeth K., et al. "Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model." Neuro-oncology 7.3 (2005): 213-224.

-Tian, Yaomei, Daoyuan Xie, and Li Yang. "Engineering strategies to enhance oncolytic viruses in cancer immunotherapy." Signal transduction and targeted therapy 7.1 (2022): 117.

-Stark, Alexander, et al. "Animal MicroRNAs confer robustness to gene expression and have a significant impact on 3′ UTR evolution." Cell 123.6 (2005): 1133-1146.

-Forterre, Alexis, et al. "A comprehensive review of cancer MicroRNA therapeutic delivery strategies." Cancers 12.7 (2020): 1852.

-Luo, Qifeng, et al. "A triple-regulated oncolytic adenovirus carrying microRNA-143 exhibits potent antitumor efficacy in colorectal cancer." Molecular Therapy-Oncolytics 16 (2020): 219-229.

-Sakuda, Tomohiko, et al. "Development of an oncolytic recombinant vesicular stomatitis virus encoding a tumor-suppressor microRNA." Anticancer Research 40.11 (2020): 6319-6325.

-Jia, Yang, et al. "Extremely low organ toxicity and strong antitumor activity of miR-34-regulated oncolytic coxsackievirus B3." Molecular Therapy-Oncolytics 12 (2019): 246-258.

-Ma, Rui, et al. "The emerging field of oncolytic virus-based cancer immunotherapy." Trends in cancer 9.2 (2023): 122-139.

-Chan, Wing Keung, et al. "A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma." Cancer immunology research 6.7 (2018): 776-787.

-Yu, Feng, et al. "T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy." Molecular Therapy 22.1 (2014): 102-111.

-Fajardo, Carlos Alberto, et al. "Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy." Cancer research 77.8 (2017): 2052-2063.

-Freedman, Joshua D., et al. "An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells." Cancer research 78.24 (2018): 6852-6865.

-Guo, Zong Sheng, et al. "Bi-and tri-specific T cell engager-armed oncolytic viruses: next-generation cancer immunotherapy." Biomedicines 8.7 (2020): 204.

-Khalique, Hena, et al. "Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy." Journal for immunotherapy of cancer 9.4 (2021).

-Cerullo, Vincenzo, et al. "Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus." Molecular Therapy 19.9 (2011): 1737-1746.

-Soliman, Hatem, et al. "Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial." Nature Medicine 29.2 (2023): 450-457.

-Garza-Morales, Rodolfo, et al. "Temozolomide renders murine cancer cells susceptible to oncolytic adenovirus replication and oncolysis." Cancer Biology & Therapy 19.3 (2018): 188-197.

-Pandit, Bhoomika, and Maksim Royzen. "Recent development of prodrugs of gemcitabine." Genes 13.3 (2022): 466.

-Lee, Jong-Chan, et al. "Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial." Gastrointestinal endoscopy 92.5 (2020): 1044-1052.

-Saha, Dipongkor, Samuel D. Rabkin, and Robert L. Martuza. "Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma." Journal for ImmunoTherapy of Cancer 8.1 (2020).

-Schaue, Dörthe, and William H. McBride. "Opportunities and challenges of radiotherapy for treating cancer." Nature reviews Clinical oncology 12.9 (2015): 527-540.

-Colin, P. H. "Concomitant chemotherapy and radiotherapy: theoretical basis and clinical experience." Anticancer research 14.6A (1994): 2357-2361.

-Omuro, Antonio, and Lisa M. DeAngelis. "Glioblastoma and other malignant gliomas: a clinical review." Jama 310.17 (2013): 1842-1850.

-Omuro, Antonio, and Lisa M. DeAngelis. "Glioblastoma and other malignant gliomas: a clinical review." Jama 310.17 (2013): 1842-1850.

-Storozynsky, Quinn T., et al. "Radiation combined with oncolytic vaccinia virus provides pronounced antitumor efficacy and induces immune protection in an aggressive glioblastoma model." Cancer Letters 562 (2023): 216169.

-Yilmaz, Melek Tugce, Aysenur Elmali, and Gozde Yazici. "Abscopal effect, from myth to reality: from radiation oncologists' perspective." Cureus 11.1 (2019).

-Shalhout, Sophia Z., et al. "Therapy with oncolytic viruses: progress and challenges." Nature reviews Clinical oncology 20.3 (2023): 160-177.

-Vijayakumar, Gayathri, Peter Palese, and Peter H. Goff. "Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma." EBioMedicine 49 (2019): 96-105.

-Maalej, Karama Makni, et al. "CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances." Molecular Cancer 22.1 (2023): 20.

-Brown, Christine E., et al. "Regression of glioblastoma after chimeric antigen receptor T-cell therapy." New England Journal of Medicine 375.26 (2016): 2561-2569.

-Zhang, Yajun, et al. "Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients." Journal of Cancer Research and Clinical Oncology 147.12 (2021): 3725-3734.

-Qu, Jingjing, et al. "Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives." Cancer immunology, immunotherapy 70 (2021): 619-631.

-Evgin, Laura, et al. "Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice." Science translational medicine 14.640 (2022): eabn2231.

-Santos, João Manuel, et al. "Adenovirus coding for interleukin-2 and tumor necrosis factor alpha replaces lymphodepleting chemotherapy in adoptive T cell therapy." Molecular Therapy 26.9 (2018): 2243-2254.

-Chen, Tianyue, et al. "IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy." Journal for ImmunoTherapy of Cancer 9.1 (2021).

-Huang, Jianhan, et al. "Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma." Cancer Immunology, Immunotherapy (2021): 1-13.

-Moon, Edmund K., et al. "Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines." Oncoimmunology 7.3 (2018): e1395997.

-Eckert, Elizabeth C., et al. "Generation of a tumor-specific chemokine gradient using oncolytic vesicular stomatitis virus encoding CXCL9." Molecular Therapy-Oncolytics 16 (2020): 63-74.

-Eckert, Elizabeth C., et al. "Generation of a tumor-specific chemokine gradient using oncolytic vesicular stomatitis virus encoding CXCL9." Molecular Therapy-Oncolytics 16 (2020): 63-74.

-Park, Anthony K., et al. "Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors." Science translational medicine 12.559 (2020): eaaz1863.

-Liu, Yuanyuan, et al. "Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy." Frontiers in Oncology 12 (2022): 1037934.

-Evgin, Laura, et al. "Oncolytic virus-derived type I interferon restricts CAR T cell therapy." Nature communications 11.1 (2020): 3187.

-Portillo, Ana L., et al. "Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment." Frontiers in Immunology 14 (2023): 1286750.

-Li, Tianye, et al. "CAR-NK cells for cancer immunotherapy: recent advances and future directions." Frontiers in Immunology 15 (2024): 1361194.

-Wu, Song-Yang, et al. "Natural killer cells in cancer biology and therapy." Molecular cancer 19 (2020): 1-26.

-Kochneva, G. V., et al. "Combination of oncolytic virotherapy and car t/nk cell therapy for the treatment of cancer." Molecular Biology 54 (2020): 1-12.

-Pan, Kevin, et al. "CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy." Journal of Experimental & Clinical Cancer Research 41.1 (2022): 119.

-Fang, Fang, et al. "Advances in NK cell production." Cellular & Molecular Immunology 19.4 (2022): 460-481.

-Liu, Enli, et al. "Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors." New England Journal of Medicine 382.6 (2020): 545-553.

-Chen, Xilin, et al. "A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases." Oncotarget 7.19 (2016): 27764.

-Bruni, Daniela, Helen K. Angell, and Jérôme Galon. "The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy." Nature Reviews Cancer 20.11 (2020): 662-680.

-Pruneri, Giancarlo, Andrea Vingiani, and Carsten Denkert. "Tumor infiltrating lymphocytes in early breast cancer." The Breast 37 (2018): 207-214.

-Ye, Kai, et al. "An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ." Molecular Therapy 30.12 (2022): 3658-3676.

-Havunen, Riikka, et al. "Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive cell therapy." Molecular Therapy-Oncolytics 4 (2017): 77-86.

-Santos, Joao, et al. "Systemic delivery of oncolytic adenovirus to tumors using tumor-infiltrating lymphocytes as carriers." Cells 10.5 (2021): 978.

-Friedman, Gregory K., et al. "Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas." New England Journal of Medicine 384.17 (2021): 1613-1622.

-Todo, Tomoki, et al. "Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial." Nature medicine 28.8 (2022): 1630-1639.

-Nakao, Shinsuke, et al. "Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade." Science translational medicine 12.526 (2020): eaax7992.

-Lu, Yuan, et al. "Strategies to package recombinant Adeno-Associated Virus expressing the N-terminal gasdermin domain for tumor treatment." Nature Communications 12.1 (2021): 7155.

-Phillips, Lynette M., et al. "An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus." Neuro-oncology 23.11 (2021): 1911-1921.

-Kanaya, Nobuhiko, et al. "Immune modulation by telomerase-specific oncolytic adenovirus synergistically enhances antitumor efficacy with anti-PD1 antibody." Molecular Therapy 28.3 (2020): 794-804.

-Liang, Yuzhi, et al. "Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration." Theranostics 13.15 (2023): 5452.

-Ishino, Ryo, et al. "Oncolytic virus therapy with HSV-1 for hematological malignancies." Molecular Therapy 29.2 (2021): 762-774.

-Morales-Molina, Alvaro, et al. "Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma." Journal for ImmunoTherapy of Cancer 9.3 (2021).

-Rivadeneira, Dayana B., et al. "Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance." Immunity 51.3 (2019): 548-560.

-Rivadeneira, Dayana B., et al. "Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance." Immunity 51.3 (2019): 548-560.

-Zhang, Liming, et al. "Reshaping the immune microenvironment by oncolytic herpes simplex virus in murine pancreatic ductal adenocarcinoma." Molecular Therapy 29.2 (2021): 744-761.

-Li, Feng, et al. "CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency." Journal for immunotherapy of cancer 8.1 (2020).

-Zuo, Shuguang, et al. "An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade." Journal for immunotherapy of cancer 9.12 (2021).

-Wang, Ruikun, et al. "CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model." Journal for ImmunoTherapy of Cancer 10.1 (2022).

-Liu, Shiyu, et al. "OX40L-armed oncolytic virus boosts T-cell response and remodels tumor microenvironment for pancreatic cancer treatment." Theranostics 13.12 (2023): 4016.

-Yoo, So Young, et al. "Overcoming tumor resistance to oncolyticvaccinia virus with anti-PD-1-based combination therapy by inducing antitumor immunity in the tumor microenvironment." Vaccines 8.2 (2020): 321.

-Santos, João Manuel, et al. "Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity." Journal for immunotherapy of cancer 8.1 (2020).

-Groeneveldt, Christianne, Jasper van den Ende, and Nadine van Montfoort. "Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?." Cytokine & Growth Factor Reviews 70 (2023): 1-12.

-Salmasi, Zahra, et al. "Mesenchymal stem cells engineered by modified polyethylenimine polymer for targeted cancer gene therapy, in vitro and in vivo." Biotechnology Progress 36.6 (2020): e3025.

-Kimbrel, Erin A., and Robert Lanza. "Next-generation stem cells—ushering in a new era of cell-based therapies." Nature Reviews Drug Discovery 19.7 (2020): 463-479.

-Taheri, Mojtaba, et al. "Nanotechnology and bioengineering approaches to improve the potency of mesenchymal stem cell as an off‐the‐shelf versatile tumor delivery vehicle." Medicinal Research Reviews (2024).

-Seyed-Khorrami, Seyed-Mahmood, et al. "MSCs loaded with oncolytic reovirus: migration and in vivo virus delivery potential for evaluating anti-cancer effect in tumor-bearing C57BL/6 mice." Cancer Cell International 21.1 (2021): 244.

-Choi, Soojin, et al. "Enhanced tumor targeting and timely viral release of mesenchymal stem cells/oncolytic virus complex due to GRP78 and inducible E1B55K expressions greatly increase the antitumor effect of systemic treatment." Molecular Therapy-Oncolytics 27 (2022): 26-47.

-Jazowiecka-Rakus, Joanna, et al. "Myxoma virus-loaded mesenchymal stem cells in experimental oncolytic therapy of murine pulmonary melanoma." Molecular Therapy-Oncolytics 18 (2020): 335-350.

-Hammad, Mohamed, et al. "Neural stem cells improve the delivery of oncolytic chimeric orthopoxvirus in a metastatic ovarian cancer model." Molecular Therapy-Oncolytics 18 (2020): 326-334.

-Jazowiecka-Rakus, Joanna, et al. "Myxoma virus expressing LIGHT (TNFSF14) pre-loaded into adipose-derived mesenchymal stem cells is effective treatment for murine pancreatic adenocarcinoma." Cancers 13.6 (2021): 1394.

-Ho, Chun-Te, et al. "Combination of mesenchymal stem cell-delivered oncolytic virus with prodrug activation increases efficacy and safety of colorectal cancer therapy." Biomedicines 9.5 (2021): 548.

-Ren, Yi, et al. "Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option." Frontiers in immunology 13 (2022): 961796.

-Feng, Yan, et al. "Exposure–response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma." Clinical Cancer Research 19.14 (2013): 3977-3986.

-Bonaventura, Paola, et al. "Cold tumors: a therapeutic challenge for immunotherapy." Frontiers in immunology 10 (2019): 168.

-Hwang, June Kyu, JinWoo Hong, and Chae-Ok Yun. "Oncolytic viruses and immune checkpoint inhibitors: preclinical developments to clinical trials." International journal of molecular sciences 21.22 (2020): 8627.

-Koski, Anniina, et al. "Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF." Molecular Therapy 18.10 (2010): 1874-1884.

-Koski, Anniina, et al. "Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF." Molecular Therapy 18.10 (2010): 1874-1884.

-Ranki, Tuuli, et al. "Phase I study with ONCOS-102 for the treatment of solid tumors–an evaluation of clinical response and exploratory analyses of immune markers." Journal for immunotherapy of cancer 4 (2016): 1-18.

-Shoushtari, Alexander N., et al. "Pilot study of ONCOS-102 and pembrolizumab: remodeling of the tumor microenvironment and clinical outcomes in anti–PD-1–resistant advanced melanoma." Clinical Cancer Research 29.1 (2023): 100-109.

-Nassiri, Farshad, et al. "Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial." Nature medicine 29.6 (2023): 1370-1378.

-Sivanandam, Venkatesh, et al. "Oncolytic viruses and immune checkpoint inhibition: the best of both worlds." Molecular Therapy-Oncolytics 13 (2019): 93-106.

-Bommareddy, Praveen K., et al. "Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma." American journal of clinical dermatology 18.1 (2017): 1-15.

-Rohaan, Maartje W., et al. "Neoadjuvant nivolumab+ T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial." BMC cancer 22.1 (2022): 851.

-Ng Tang, Derek, et al. "Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy." Cancer immunology research 1.4 (2013): 229-234.

-Tian, Yuhang, et al. "New aspects of ultrasound-mediated targeted delivery and therapy for cancer." International Journal of Nanomedicine (2020): 401-418.

-Chen, Kuo-Wei, et al. "Targeting nanoparticle-conjugated microbubbles combined with ultrasound-mediated microbubble destruction for enhanced tumor therapy." Pharmacological Research 186 (2022): 106532.

-Avry, François, et al. "Microbubble-assisted ultrasound for imaging and therapy of melanoma skin cancer: A systematic review." Ultrasound in Medicine & Biology 48.11 (2022): 2174-2198.

-Bachu, Vismaya S., et al. "High-intensity focused ultrasound: a review of mechanisms and clinical applications." Annals of biomedical engineering 49.9 (2021): 1975-1991.

-Nande, Rounak, Candace M. Howard, and Pier Paolo Claudio. "Ultrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of art." Oncolytic virotherapy (2015): 193-205.

-Bazan-Peregrino, Miriam, et al. "Ultrasound-induced cavitation enhances the delivery and therapeutic efficacy of an oncolytic virus in an in vitro model." Journal of Controlled Release 157.2 (2012): 235-242.

-Greco, Adelaide, et al. "Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach." Molecular Therapy 18.2 (2010): 295-306.

-Okunaga, S., et al. "Ultrasound as a method to enhance antitumor ability of oncolytic herpes simplex virus for head and neck cancer." Cancer Gene Therapy 22.3 (2015): 163-168.

-Zhou, Li-Qiang, et al. "Ultrasound nanotheranostics in fighting cancer: advances and prospects." Cancer letters 470 (2020): 204-219.

-Mukhopadhyay, Debasmita, et al. "Ultrasound-mediated cancer therapeutics delivery using micelles and liposomes: a review." Recent Patents on Anti-Cancer Drug Discovery 16.4 (2021): 498-520.

-Menotti, Laura, et al. "HSV as a platform for the generation of retargeted, armed, and reporter-expressing oncolytic viruses." Viruses 10.7 (2018): 352.

-Yamamoto, Yuki, et al. "Recent advances in genetic modification of adenovirus vectors for cancer treatment." Cancer science 108.5 (2017): 831-837.

-Berkeley, Robert A., et al. "Antibody-neutralized reovirus is effective in oncolytic virotherapy." Cancer immunology research 6.10 (2018): 1161-1173.

-Kim, Janice, et al. "Stem cell-based cell carrier for targeted oncolytic virotherapy: translational opportunity and open questions." Viruses 7.12 (2015): 6200-6217.

-Garofalo, Mariangela, et al. "Polymer coated oncolytic adenovirus to selectively target hepatocellular carcinoma cells." Pharmaceutics 13.7 (2021): 949.

-Na, Youjin, et al. "Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration." Journal of Controlled Release 305 (2019): 75-88.

-Wang, Yalong, et al. "Liposome encapsulation of oncolytic virus M1 to reduce immunogenicity and immune clearance in vivo." Molecular Pharmaceutics 16.2 (2019): 779-785.

-Garcia-Carbonero, Rocio, et al. "Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection." Journal for immunotherapy of cancer 5 (2017): 1-13.

-Samson, Adel, et al. "Neoadjuvant intravenous oncolytic vaccinia virus therapy promotes anticancer immunity in patients." Cancer immunology research 10.6 (2022): 745-756.

-Kennedy, Edward M., et al. "Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer." Nature Communications 13.1 (2022): 5907.

-Hom, Vania, et al. "Development of a nursing policy for the administration of an oncolytic virus in the outpatient setting." Seminars in Oncology Nursing. Vol. 35. No. 5. WB Saunders, 2019.

-Gutzmer, Ralf, et al. "Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe." European Journal of Dermatology 28 (2018): 736-749.

-Harrington, Kevin J., et al. "A practical guide to the handling and administration of talimogene laherparepvec in Europe." OncoTargets and therapy (2017): 3867-3880.

-Macedo, Nicholas, et al. "Clinical landscape of oncolytic virus research in 2020." Journal for immunotherapy of cancer 8.2 (2020).

-Martin, Nikolas Tim, and John Cameron Bell. "Oncolytic virus combination therapy: killing one bird with two stones." Molecular Therapy 26.6 (2018): 1414-1422.

-Sharp, Daniel W., and Edmund C. Lattime. "Recombinant poxvirus and the tumor microenvironment: oncolysis, immune regulation and immunization." Biomedicines 4.3 (2016): 19.

-Pol, Jonathan G., et al. "Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials." Oncoimmunology 8.1 (2019): e1512329.

-Zamarin, Dmitriy, et al. "Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy." Science translational medicine 6.226 (2014): 226ra32-226ra32.

-Benencia, Fabian, et al. "HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer." Molecular Therapy 12.5 (2005): 789-802.

-Li, Jun, et al. "Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity." Neoplasia 14.12 (2012): 1115-IN1.

-Feins, Steven, et al. "An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer." American journal of hematology 94.S1 (2019): S3-S9.

-Ajina, Adam, and John Maher. "Prospects for combined use of oncolytic viruses and CAR T-cells." Journal for immunotherapy of cancer 5 (2017): 1-27.

-Moesta, Achim K., et al. "Local delivery of OncoVEXmGM-CSF generates systemic antitumor immune responses enhanced by cytotoxic T-lymphocyte–associated protein blockade." Clinical Cancer Research 23.20 (2017): 6190-6202.

-Nishio, Nobuhiro, et al. "Armed oncolytic virus enhances immune functions of chimeric antigen receptor–modified T cells in solid tumors." Cancer research 74.18 (2014): 5195-5205.

-Yu, Feng, et al. "T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy." Molecular Therapy 22.1 (2014): 102-111.

-Jin, Jing, et al. "Bispecific antibody expressed by an oncolytic herpes simplex virus type 2 can transform heterologous T cells into uniform tumor killer cells." Human Gene Therapy 33.11-12 (2022): 649-663.

-Fajardo, Carlos Alberto, et al. "Oncolytic adenoviral delivery of an EGFR-targeting T-cell engager improves antitumor efficacy." Cancer research 77.8 (2017): 2052-2063.

-Freedman, Joshua D., et al. "Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies." EMBO molecular medicine 9.8 (2017): 1067-1087.

-Pearl, Taylor M., et al. "Oncolytic virus-based cytokine expression to improve immune activity in brain and solid tumors." Molecular Therapy-Oncolytics 13 (2019): 14-21.

-Tanoue, Kiyonori, et al. "Armed oncolytic adenovirus–expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors." Cancer research 77.8 (2017): 2040-2051.

-Ge, Yan, et al. "Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety." Journal for immunotherapy of cancer 8.1 (2020).

-Ge, Yan, et al. "Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety." Journal for immunotherapy of cancer 8.1 (2020).

-Nakao, Shinsuke, et al. "Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade." Science translational medicine 12.526 (2020): eaax7992.

-Chard, Louisa S., Nicholas R. Lemoine, and Yaohe Wang. "New role of Interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer." Oncoimmunology 4.9 (2015): e1038689.

-Kowalsky, Stacy J., et al. "Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade." Molecular Therapy 26.10 (2018): 2476-2486.

-Chen, Tianyue, et al. "IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy." Journal for ImmunoTherapy of Cancer 9.1 (2021).

-Deng, Lili, et al. "IL-24-armed oncolytic vaccinia virus exerts potent antitumor effects via multiple pathways in colorectal cancer." Oncology Research 28.6 (2021): 579.

-Yang, Min, et al. "IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity." Cancer Immunology, Immunotherapy (2021): 1-15.

-Bartee, Mee Y., Katherine M. Dunlap, and Eric Bartee. "Tumor-localized secretion of soluble PD1 enhances oncolytic virotherapy." Cancer research 77.11 (2017): 2952-2963.

-Kleinpeter, Patricia, et al. "Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition." Oncoimmunology 5.10 (2016): e1220467.

-Engeland, Christine E., et al. "CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy." Molecular Therapy 22.11 (2014): 1949-1959.

-Passaro, Carmela, et al. "Arming an oncolytic herpes simplex virus type 1 with a single-chain fragment variable antibody against PD-1 for experimental glioblastoma therapy." Clinical Cancer Research 25.1 (2019): 290-299.

-Dong, Chen, et al. "ICOS co-stimulatory receptor is essential for T-cell activation and function." Nature 409.6816 (2001): 97-101.

-Zamarin, Dmitriy, et al. "Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity." Nature communications 8.1 (2017): 14340.

-Croft, Michael, et al. "The significance of OX40 and OX40L to T‐cell biology and immune disease." Immunological reviews 229.1 (2009): 173-191.

-Durham, Nicholas M., et al. "Oncolytic VSV primes differential responses to immuno-oncology therapy." Molecular Therapy 25.8 (2017): 1917-1932.

-Jiang, Hong, et al. "Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination." Cancer research 77.14 (2017): 3894-3907.

-Andtbacka, Robert HI, et al. "Talimogene laherparepvec improves durable response rate in patients with advanced melanoma." Journal of clinical oncology 33.25 (2015): 2780-2788.

-Alberts, Pēteris, et al. "The advent of oncolytic virotherapy in oncology: The Rigvir® story." European journal of pharmacology 837 (2018): 117-126.

-Andtbacka, Robert HI, et al. "Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma." J Clin Oncol 35.15_suppl (2017): 9510.

-Ferris, Robert L., et al. "Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV-patients with refractory and superficial cancers." (2014): 6082-6082.

-Yu, Wang, and Hu Fang. "Clinical trials with oncolytic adenovirus in China." Current cancer drug targets 7.2 (2007): 141-148.

-Liang, Min. "Oncorine, the world first oncolytic virus medicine and its update in China." Current cancer drug targets 18.2 (2018): 171-176.

-Xia, Zhong-Jun, et al. "Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus." Ai zheng= Aizheng= Chinese journal of cancer 23.12 (2004): 1666-1670.

-Stupp, Roger, et al. "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma." New England journal of medicine 352.10 (2005): 987-996.

-Todo, Tomoki, et al. "Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial." Nature medicine 28.8 (2022): 1630-1639.

-Friedman, Gregory K., et al. "Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas." New England Journal of Medicine 384.17 (2021): 1613-1622.

-Markert, James M., et al. "A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses." Molecular Therapy 22.5 (2014): 1048-1055.

-Gállego Pérez-Larraya, Jaime, et al. "Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma." New England Journal of Medicine 386.26 (2022): 2471-2481.

-Lang, Frederick F., et al. "Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma." Journal of clinical oncology 36.14 (2018): 1419-1427.

-Beasley, Georgia M., et al. "Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma." Journal for Immunotherapy of Cancer 9.4 (2021).

-Desjardins, Annick, et al. "Recurrent glioblastoma treated with recombinant poliovirus." New England Journal of Medicine 379.2 (2018): 150-161.

-Burke, James M., et al. "A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer." The Journal of urology 188.6 (2012): 2391-2397.




DOI: http://dx.doi.org/10.52155/ijpsat.v49.1.7020

Refbacks

  • There are currently no refbacks.


Copyright (c) 2025 Maged Naser

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.